Author: Editor

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Margaret Oakes, Specialist Counselling Psychologist at Berkshire Healthcare NHS Foundation Trust, Bracknell, UK, and Kevin Johnson, Physical Activity Lead at Macmillan Cancer Support, London, UK, discuss the role of physical activity for people living with and beyond cancer and the rationale for psychological skills training for Physical Activity Specialists to improve the management of psychological distress associated with cancer and cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Does the development of resistant clones in multiple myeloma affect long-term treatment?

To what extent are you able to achieve long-term treatment goals in your patients with multiple myeloma?

Are there practical considerations for long-term treatment of multiple myeloma?

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michael Mawhinney, doctoral research student, Oxford Brookes University, Oxford, UK, discusses the role of healthcare professionals in addressing cancer patients’ sexuality needs and the role of assessment models, such as BETTER (Bring up sexuality; Explain role of sexuality in quality of life; Tell about and facilitate resources; Timing critical; Educate patient and partner; Record in health record), for raising sexual issues. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Leading researcher Dr. Kanti Rai has devoted his career to understanding and classifying CLL. After Dr. Rais return from the iwCLL conference, Patient Power founder Andrew Schorr visited with Dr. Rai to learn more about progress in CLL biology and how it could positively impact treatment options. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

From our latest Ask the Expert segment with MPN expert Dr. Bart Scott from Seattle Cancer Care Alliance (SCCA), he answers viewer Verns question, What is the DIPSS scoring system, and how is it used in the monitoring of MPNs? Dr. Scott explains risk scores associated with survival and how that affects choices for treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michelle Taylor, Clinical Nurse Specialist, of The Great Western Hospital, Swindon, and Jasmine Hebden, Clinical Nurse Specialist, of The Great Western Hospital, Swindon, UK, discuss the introduction of new patient-focused initiatives designed to address patients unmet needs at the end of treatment in haemato-oncology, including combining interventions such as holistic-needs assessment and support-events provision. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Debbie Gillen, of The Christie NHS Foundation Trust, Manchester, UK, discusses an acute oncology education campaign that was designed to provide acute oncology education to community and primary care teams, and thereby improve the standards of awareness and support for patients outside of the hospital setting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Lisa Wells, Macmillan Lung Cancer Clinical Nurse Specialist, of Northampton General, Hospital NHS Trust, Northampton, UK, discusses a new lung cancer pathway project, which was designed to improve the quality of treatment and care patients receive through approaches that address the individual patient’s needs. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Andrew Turner, discusses a qualitative study of the self-management needs of men that have survived prostate and testicular cancer for the development of the web-based, self-management programme, iHOPE. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, explains the clinical impact of emerging treatments, including abiraterone acetate and enzalutamide in both post-chemotherapy and pre-chemotherapy settings, on the care and quality of life of patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, which attracts cancer nurses from around the United Kingdom and beyond, Catherine Oakley, PhD, UKONS President 20142016, and Chemotherapy Nurse Consultant at Guy’s and St Thomas’ NHS Foundation Trust, London, UK, explains the theme of the conference, Patient Safety, and the four subsidiary topics, Haemato-Oncology Nursing, Early Diagnosis and Treatment, Supporting Cancer Nurses and Initiatives in the Treatment and Care of People with Cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, explains that genetic differences between primary and metastatic breast cancer may have important clinical implications, including for the identification of biomarkers for disease progression. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK, explains that nutrition has an important role in the treatment of cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of clinical trials reported at the European Cancer Congress (ECC) 2015 in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Can MPN patients develop biological markers that influence their current therapies? Yes, says MPN expert Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center. Dr. Verstovsek discusses genetic mutations and drug resistance and what researchers are doing to stay ahead. He remains optimistic for the future as clinical trials continue to indicate increased benefits to the MPN patient population. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

How has the field of MPNs expanded in the last 10 years? Meet MPN expert Dr. Laura Michaelis, Clinician and Clinical Researcher at Medical College of Wisconsin. She sat down with Andrew to discuss the evolving landscape of MPNs and new scientific advantages that have her and other researchers excited. Using the analogy of a garden and weeds, Dr. Michaelis walks us through genetic aberrations, JAK-STAT pathway, driver mutations, and precision medicine, ending with the advent of social medias role in accelerating communication in the field of MPNs. Listen as she comments on all this progression as eventually curing people,…

Fresh from the iwCLL, CLL expert Dr. William Plunkett, Professor in the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center shares the latest news on CLL therapeutics with Andrew. Dr. Plunkett is on the cutting edge of biological therapy and speaks confidently of the progression of CLL treatments. Listen as he states, The future is bright for development ofdemonstrably curative CLL therapies. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Can patient care be coordinated regardless of what country you live in? When should an MPN patient start seeking expert care? MPN expert Dr. Bart Scott, Director of Hematology and Hematologic Malignancies at Seattle Cancer Care Alliance, answers these questions. Dr. Scott also discusses when an MPN patient may require changes to their treatment and what those options are, including clinical trials. Listen as Dr. Scott explains why this is a hopeful time for MPN patients. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ |…

At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that strategies to manage progression in patients with non-small cell lung cancer (NSCLC) should be tailored to individual patients, as there may be a need to address pharmacologic issues or the molecular emergence of new resistant clones. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study, which was designed to evaluate the prognostic and predictive value of HER2-status of circulating tumour cells in patients with metastatic breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Toni Choueiri, MD of the Dana-Farber Cancer Institute welcomes viewers to the 14th International Kidney Cancer Symposium 2015

Toni Choueiri, MD of the Dana-Farber Cancer Institute How Does the Axitinib Plus Pembrolizumab study impact future research?

Toni Choueiri, MD of the Dana-Farber Cancer Institute discusses the Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve PatientsWith Advanced Renal Cell Carcinoma

Michael Bassetti MD PhD of the University of Wisconsin Madison discusses the next steps Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer what are the next steps?

Michael Bassetti MD PhD of University of Wisconsin Madison discusses What’s the Impact to Physicians Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer

Michael Bassetti MD PhD of the University of Wisconsin Madison discusses Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer an Overview

Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown Primary or CUP. For more information, visit http://www.cancertypeid.com

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the impact of the Oncotype DX® Breast Cancer Assay, a multigene assay that stratifies patients into risk groups that are associated with distant recurrence and response to adjuvant chemotherapy, on treatment decisions for patients with early stage breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a study that was designed to determine whether seropositivity to a panel of tumour antigens was associated with a risk of relapse in patients with stage II and III melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Maria De Santis, MD, of the University of Warwick, Warwick, UK, discusses the initial results of ASPIRE-PCa, a prospective, global observational study that was designed to describe patterns of care and outcomes for men with late-stage prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School of Oncology-organised multidisciplinary Task Force, which focuses on reviewing access to innovation in all fields of oncology. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy, safety and predictive biomarkers from POPLAR, a randomised phase 2 clinical trial of atezolizumab monotherapy versus docetaxel in patients with second- or third-line non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia, discusses the impact of baseline genetic heterogeneities on progression-free survival in patients with advanced BRAF V600-mutated melanoma treated with cobimetinib plus vemurafenib in the phase 3 coBRIM clinical trial. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Eric Pujade-Lauraine, MD, PhD, of Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France, discusses AURELIA, an open-label, randomised, phase 3 clinical trial that was designed to evaluate bevacizumab combined with chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel or topotecan) for patients with platinum-resistant recurrent ovarian cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, of Universitätsklinikum Essen, Essen, Germany, discusses the advances in the understanding of BRAF-mutant melanoma biology, which involves the constitutive activation of the MAPK pathway, that have led to the development of new targeted therapies for patients with metastatic disease. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Multigene assays may provide clinically complementary information to classic clinicopathological tumour features, such as tumour size and grade, in breast cancer. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, reviews the predictive and prognostic value of currently available multigene assays for the management of patients with early stage breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

The Oncotype DX® Breast Cancer Assay, a multigene assay, stratifies breast cancer patients into groups that are at low, intermediate or high risk for distant recurrence and guides decision making for adjuvant chemotherapy. At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, explains the factors that were associated with the implementation of the Oncotype DX assay in different healthcare systems. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Benjamin Besse, MD, PhD, of Institut Gustave Roussy, Villejuif, France, discusses BIRCH, a phase 2, single-arm clinical trial of atezolizumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, as first-line or subsequent therapy for patients with locally advanced or metastatic PD-L1-selected non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Bartomeu Massuti, MD, of Hospital General de Alicante, Alicante, Spain, discusses the Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) phase 2 BELIEF clinical trial, which evaluated erlotinib and bevacizumab in patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without the T790M mutation. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety data from the phase 1b part of MASTERKEY-265 , a phase 1b/3 clinical trial that was designed to evaluate the treatment of talimogene laherparepvec (T-VEC), a herpes simplex virus-1, and pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with unresectable stage IIIB-IV melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Enriqueta Felip – Targeted therapies in ALK-positive NSCLC

@OncEd Presents Dr. Simon Raphael – Actionable biomarkers in NSCLC: EGFR and ALK

@OncEd Presents Dr. Keith Flaherty – Integrating new treatment options for melanoma

@OncEd Presents Dr. Keith Flaherty – An expert’s perspective on frequently asked questions on BRAF V600-mutated advanced melanoma

@OncEd Presents – Dr. Natasha Leighl & Dr. David Hogg – Immune Response Vs. RECIST Criteria

@OncEd Presents Dr. Lori Wood – Optimizing Outcomes in Advanced Prostate Cancer

Chris Carrigan of the National Cancer Intelligence Network (NCIN), discusses the uses of the enormous amount of data collected by NHS on a daily basis, to improve the outcomes of cancer patients.

Karen Kennedy, PhD, Director of the National Cancer Research Institute (NCRI), gives an overview of the 2015 NCRI Cancer Conference. The conference covers the whole range of cancer research from prevention and early diagnosis through basic science, translational science, clinical research, survivorship and palliative care research. Karen Kennedy also discusses recent NCRI initiatives on pathology research, and long-standing initiatives on radiotherapy and survivorship.

Kristian Helin, PhD gives an overview of his talk on epigenetic targets in cancer presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he explains what is epigenetics, it’s role in cancer cells and the importance of developing novel cancer treatments that inhibit the regulation of this mechanism.

Robert Coleman, MBBS, MD, FRCP, a trustee of Breast Cancer Now, discusses the goals of the newly formed charity that resulted from the combination of Breakthrough Breast Cancer and Breast Cancer Campaign. The charity has set the goal to prevent breast cancer death by 2050, which will be achieved by continuing to provide funding to breast cancer treatment, but also focusing on prevention, policies and economics in breast cancer.

Kevin Brindle, PhD gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he described a new technique called nuclear spin hyperpolarization, that can increase the sensitivity of the magnetic resonance by 10,000 fold. This technique can have several uses, including detection of treatment response and investigation of tumour microenvironment. In his talk Kevin Brindle focuses on the use of this technique in brain tumours.

Harpal Kumar, MA MEng MBA DSc gives an overview of his session at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where he discusses the efforts of the National Awareness and Early Diagnosis Initiative (NAEDI) to develop a better understanding of the contribution of late diagnosis to the UK’s relatively poor cancer survival rates and develop strategies to address this.

Miriam Johnson, MD gives an overview of a session at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, that focuses on the importance of providing GPs and oncologists with a tool that can help them systematically assess the patient and carer needs. These needs can range from physical and psychological symptoms to legal, financial and work related matters that could directly affect the quality of life and cancer patients and their carers. The session hosted talk by Irene Higginson, Wei Gao and Christina Remsenthaler.

With the advent of unlocking genetic code, the cancer community has now been introduced to the concept of immunotherapy. What does this mean specifically for MPN patients? For MPN expert Dr. Srdan Verstovsek of MD Anderson Cancer Center, genetics hold many answers but add a level of complexity related to prognosis and treatment. Dr. Mark Heaney of Columbia University Cancer Center views genetics in terms of interpreting how aggressive the disease may be, while Bob Rosen, patient advocate and Chairman of MPN Research Foundation, suggests that patients put the role of genetics into perspective by connecting with a specialist. Get…

In this segment of The Conversation, MPN Edition, Dr. Srdan Verstovsek of MD Anderson Cancer Center, MPN expert Dr. Mark Heaney of Columbia University Cancer Center, and Bob Rosen, Chair of MPN Research Foundation share their insight and views on clinical trial participation. Listen closely as the guests discuss the differences between the REVEAL study and the PEGASYS trial, highlighting the outcomes, reasons, and options for both participation and non-participation in clinical trials and observational studies. As Bob Rosen says, it’s a “balancing act for patients and their doctors to decide.” Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube |…

CLL patients with certain genetic markers are considered to be high risk and their options for treatment have historically been limited. CLL expert Dr. Jeff Sharman joins Patient Power to discuss emerging approaches to treating high-risk CLL currently being studied in clinical trials. Sponsored through an educational grant from TG Therapeutics. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

MPN experts Dr. Mark Heaney of Columbia University Cancer Center and Dr. Srdan Verstovek of MD Anderson Cancer Center examine the expanding polycythemia vera (PV) armamentarium, answering the question, “Where are we now?” Dr. Heaney discusses second generation inhibitors and customization of treatment, while Dr. Verstovek focuses on combination therapies and expanded options coming from interferon trials in Europe. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Dr. Michael Keating, a leading researcher from MD Anderson Cancer Center, has had a career that spans decades and has witnessed the evolution of CLL research. Andrew Schorr, the founder of Patient Power, sat down with Dr. Keating to discuss promising developments in CLL research and Dr. Keatings ongoing commitment: to stay alive until CLL is cured. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Paolo Boffetta, MD, MPH gives an overview of his talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. In his talk he discusses how the burden of cancer can be reduced by dietary modifications. Prof. Boffetta also highlights the importance of having a healthy and balanced diet, which includes fruit, vegetables and protein, and to try and avoid focusing on one specific food item or chemical element.

Rebecca Fitzgerald, MD, FAAD gives an overview of a session presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, focusing on molecular testing for early cancer diagnosis. The session included talks by Marc Tischkowitz and Peter Sasieni. Marc Tischkowitz focused on tests for genetic predisposition of ovarian cancer and results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study, whilst Peter Sasieni addressed the bigger question about biomarkers and how they are useful at different stages of early detection. Rebecca Fitzgerald also introduces Cytosponge, a non-endoscopic cell collection tool that in combination with oesophageal biomarkers can aid…

Chad Creighton of the Baylor College of Medicine: “How does the Papillary RCC: The Cancer Genome Atlas (TCGA) impact Physicians?”

Chad Creighton of Baylor College of Medicine discusses the next steps for Papillary RCC: The Cancer Genome Atlas (TCGA)

Chad Creighton of Baylor College of Medicine discusses a short overview of the Papillary RCC: The Cancer Genome Atlas (TCGA)

Tim Hunt, FRS, FMedSci describes the path that led him to identify cyclin-dependent kinases (CDK), along with colleagues Paul Nurse and Leland Hartwell, that would eventually lead to the award of a Nobel Prize in Physiology or Medicine in 2001.

Jack Cuzick, PhD, FMedSci, FRCP(hon), of the Queen Mary University of London, UK gives an overview of the session ‘Prevention is better than cure’ cancer chemoprevention in 2015, presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. The session included speakers such as Andrew Chan, Sam Behjati, Dario Alessi and Henry Kitchener.

In the session ” Tumour: stroma interactions” presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, the importance of stromal interaction in the tumour environment is discussed by Kairbaan Hodivala-Dilke, Ilirjana Bajrami, Helmut G. Augustin, Jason Fleming and host Erik Sahai. Whilst it has been realised for many years that cancer is a process driven by mutations within the cells, it is also clear now that those cells also have complicated interactions with neighbouring cells and the local environment. The focus of this session was to try to understand how the complex interactions between tumour cells and stroma…

Clare Turnbull, MD, PhD, gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference, where the Genomics England clinical interpretation partnership (GeCIP) was presented. In her talk, Dr Turnbull described how the programme plans to sequence the whole genome of thousands of cancer patients recruited within the NHS. This will generate enormous data and sample resources that will be made searchable through GeCIP.

Neeraj Agarwal, MD of the Huntsman Cancer Institute presents “Molecular predictors of response and survival outcomes in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with VEGF-TKIs” at the 14th International Kidney Cancer Symposium.

Michael A. Gorin, M.D. of Johns Hopkins University School of Medicine presents “Development of an Antibody-free Method for Detecting Renal Cell Carcinoma Circulating Tumor Cells” at the 14th International Kidney Cancer Symposium.

David Gill, MD of the Huntsman Cancer Institute presents “Correlation of tumor programmed death ligand-1 (PD-L1) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in metastatic clear cell renal cell carcinoma (mccRCC).” at the 14th International Kidney Cancer Symposium.

Peter F. Thall, PhD of M.D. Anderson Cancer Center presents “Bayesian Designs for Early Phase Clinical Trials” at the 14th International Kidney Cancer Symposium.

Meredith M. Regan, ScD of the Dana-Farber Cancer Institute presents “Statistical Considerations in RCC: Biomarker-Based Studies” at the 14th International Kidney Cancer Symposium.

Wayne A. Marasco, MD, Ph.D.of the Dana-Farber Cancer Institute presents “Carbonic Anhydrdase IX: Opportunities for Immune-Based Approaches” at the 14th International Kidney Cancer Symposium

Daniel Lindner, MD, PhD of the Cleveland Clinic presents “Patient derived xenograft models and ? potential therapeutic applications” at the 14th International Kidney Cancer Symposium.

Thai Ho, M.D., Ph.D. from the Mayo Clinic Arizona presents “The Evolving Role of Chromatin and Epigenetics in RCC” at the 14th International Kidney Cancer Symposium.

Sumanta Kumar Pal, M.D. of the City of Hope Comprehensive Cancer Center presents “Applying Advanced Genomics to Therapy Selection” at the 14th International Kidney Cancer Symposium.

Brian Rini, MD of the Cleveland Clinic presents “2015 Eugene P. Schonfeld Award” at the 14th International Kidney Cancer Symposium.

Eliezer (Eli) Van Allen, MD of Dana-Farber Cancer Institute presents “Expanding the clinically actionable kidney cancer genome” at the 14th International Kidney Cancer Symposium.

Brian R. Lane, M.D., Ph.D., FACS of Spectrum Health Medical Group? presents “Molecular Prediction of Kidney Cancer Recurrence”

Thai Ho, M.D., Ph.D. from the Mayo Clinic Arizona presents “KCA Role in Developing a Research Program in Kidney Cancer Epigenetics” at the 14th International Kidney Cancer Symposium.

André P. Fay, MD of Dana-Farbe presents “Treatment of Kidney Cancer in Developing Countries ” at the 14th International Kidney Cancer Symposium

Thomas E Hutson, DO, PharmD, FACP of the Baylor-Sammons Cancer Center presents “Emerging Targeted Therapies” at the 14th International Kidney Cancer Symposium.

Laurence Albiges presents “Emerging Biomarkers of VEGF and mTOR Inhibitors in 2015” at the 14th International Kidney Cancer Symposium.

Daniel Y C Heng MD MPH FRCPC of the University of Calgary presents “Improving Patient Care Through Health Outcome Research in RCC” at the 14th International Kidney Cancer Symposium.

Stacey Kenfield, DSc gives an overview of her talk at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. Dr Kenfield talks about how lifestyle changes, such as physical activity and diet, can reduce the risk of progression of prostate cancer.

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb talks about the initiatives Macmillan Cancer Support is implementing to increase conversations about physical activity between healthcare professionals and cancer patients.

At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Justin Webb gives an overview of a new Macmillan Cancer Support initiative aimed at helping cancer patients integrate physical activity into their routine.

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains that the specific setting and utility of a tumour biomarker must be clearly defined during clinical investigation in order to generate meaningful results. In patients with early stage breast cancer, there is a need to identify new risk factors for disease outcome, which may enable the identification of patients who are likely to respond to specific therapies. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses the results to date for Trial Assigning IndividuaLized Options for Treatment (TAILORx), which is a prospective phase 3 clinical trial evaluating the utility of the Oncotype DX® Breast Cancer Assay to guide adjuvant treatment decisions in patients with ER-positive, HER2-negative, node-negative breast cancer. Promising outcomes at 5 years were reported in patients with a low Oncotype DX Recurrence Score® (RS) result, which suggests this population may be safely spared of chemotherapy. The evaluation continues in the study group comprising…

Judge Schonfeld-CEO-CureHunter Inc. presents “Speeding Drug Discovery with Computational Biology Network Graph Theory” at the 14th International Kidney Cancer Symposium.

John A. Josey, Ph.D. Peloton Therapeutics, Inc. presents “Targeting HIF-2: Myth or Reality? A First-In-Class HIF-2 Antagonist for the Treatment of clear cell Renal Cell Carcinoma: PT2385” at the 14th International Kidney Cancer Symposium.

Jeffrey Wallin, Ph.D. of Genentech presents “Opening the Floodgates to T Cells Biomarkers for the Combination of Bevacizumab and Atezolizumab in RCC” at the 14th International Kidney Cancer Symposium.

Fabian Zohren, MD PhD from Takeda presents “Inhibiting the mTOR Complex: Biology and Targets” at the 14th International Kidney Cancer Symposium.

Mark W Ball presents “Pathologic and Genomic Profiles of Exceptional Responders to Anti-PD1 Therapy in Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Toni Choueiri, MD Dana-Farber Cancer Institute presents “Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve PatientsWith Advanced Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Michael Postow, MD from Memorial Sloan Kettering Cancer Center presents “Managing Side Effects of Immune Checkpoint Blockade” at the 14th International Kidney Cancer Symposium .

Dan George, MD Duke Cancer Institute presents “Oncolytic Viruses” at the 14th International Kidney Cancer Symposium.

David McDermott, MD of Dana Farber presents “The Really Important Questions Current Immunotherapy Trials are Not Answering” at the 14th International Kidney Cancer Symposium.

Ronit Simantov, M.D. of Pfizer Oncology presents “Optimizing Therapy of RCC through Industry-Academic Collaborations” at the 14th International Kidney Cancer Symposium.

Neeraj Agarwal, MD of Huntsman Cancer Institute, University of Utah presents “Initial therapy for mRCC: High-dose IL-2 or a Checkpoint Inhibitor Trial” at the 14th International Kidney Cancer Symposium.

Hans Hammers MD, PhD of Johns Hopkins presents “Initial Therapy for mRCC: Pro: Immune Checkpoint Inhibitors” at the 14th International Kidney Cancer Symposium.

Charles G. Drake MD of Johns Hopkins Kimmel Cancer Center presents Combination Immunotherapeutic Strategies in RCC: Preclinical Rationale AND Clinical Experience

Gordon Freeman, PhD from the Dana-Farber Cancer Institute Harvard Medical School presents “The Biology of Checkpoint Inhibition” at the 14th International Kidney Cancer Symposium.

Moshe C. Ornstein MD MA of the Cleveland Clinic Taussig Cancer Institute presents “Clinical Effect of TKI Dose-Escalation after Disease Progression in Patients with Metastatic Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Andrew J. Armstrong MD ScM FACP of Duke Cancer Institute presents “Clinical Trials in Non-Clear Cell RCC” at the 14th International Kidney Cancer Symposium.

Jose A. Karam, MD, FACS of MD Anderson presents “RCC with Sarcomatoid Dedifferentiation: New Insights” at the 14th International Kidney Cancer Symposium.

Gabriel G. Malouf, MD, PhD of Pitie Salpetriere Hospital presents “Collecting Duct Renal Cell Carcinomas” at the 14th International Kidney Cancer Symposium.

Chad Creighton of Baylor College of Medicine presents “Papillary RCC: The Cancer Genome Atlas (TCGA)” at the 14th International Kidney Cancer Symposium.

Payal Kapur, M.D. of UT Southwestern Medical Center presents “Chromophobe Renal Cell Carcinoma: TCGA and UTSW Updates’ at the 14th International Kidney Cancer Symposium.

Eric Jonasch Professor of Medicine UT MD Anderson Cancer Center presents “VHL Syndrome and Hemangioblastoma Management” at the 14th International Kidney Cancer Symposium.

Paul Russo, MD, FACS of Cornell University presents “Partial Nephrectomy 15 YEARS OF PROGRESS” at the 14th International Kidney Cancer Symposium.

Suzanne B. Stewart-Merrill. MD presents ” Oncologic Surveillance Following Surgical Resection for Renal Cell Carcinoma: A Novel Risk-based Approach” at the 14th International Kidney Cancer Symposium.

Michael L. Blute Jr,. MD of the University of Wisconsin presents “Novel 3D volume analysis reveals primary tumor diameter is a poor predictor of tumor volume; does tumor burden actually predict survival after cytoreductive nephrectomy?’ at the 14th International Kidney Cancer Symposium.

Sarah P. Psutka M.D., M.Sc of Cook County, Chicago presents “Management of Local Recurrence After Radical Nephrectomy” at the 14th International Kidney Cancer Symposium.

E. Jason Abel, M.D. of the University of Wisconsin presents “Patient Selection for Surgery in RCC with Thrombus” at the 14th International Kidney Cancer Symposium.

Dipen J. Parekh, MD of the University of Miami Miller School of Medicine presents “WARMING UP TO ISCHEMIA” at the 14th International Kidney Cancer Symposium

Karim Touijer , MD, MPH from the Memorial Sloan-Kettering Cancer Center presents “Partial Nephrectomy: Does Ischemia Matter?” at the 14th International Kidney Cancer Symposium

James Porter of the Swedish Medical Center Seattle, WA presents “Minimally Invasive Lymphadenectomy for Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.

Steven C. Campbell, MD, PhD of The Cleveland Clinic discusses “Optimal Treatment of cT1b Renal Mass in Patient with Normal GFR: a Role for Radical Nephrectomy?” at the 14th International Kidney Cancer Symposium.

Michael A. Gorin, M.D. of Johns Hopkins University School of Medicine discusses “Novel Imaging Techniques in RCC” at the 14th International Kidney Cancer Symposium.

Michael Bassetti MD PhD of the University of Wisconsin Madison discusses “University of Wisconsin Madison” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

R. Houston Thompson, MD Professor of Urology Mayo Clinic discusses “Partial Nephrectomy or Ablation for Small Renal Mass” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Michael A.S. Jewett discusses “Surveillance is the Best Treatment for T1a RCC in a healthy 65 year old patient” at the Fourteenth International Kidney Cancer Symposium Miami, Florida, USA, November 6th , 2015 www.kidneycancersymposium.com

Stephen A. Boorjian, MD of the Mayo Clinic, Rochester, MN discusses ” CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Bradley C. Leibovich, MD, FACS , Mayo Clinic debates ” Renal Mass Biopsy Should Be Used Sparingly in patients with SRM” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Tony Finelli, MD, MSc, FRCSC Head, Division of Urology GU Site Lead, Princess Margaret Cancer Center debates the Pro side to “Renal Mass Biopsy Should be Used for Most SRM – PRO” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

A Ari Hakimi MD Memorial Sloan Kettering Cancer Center brings an “Update on Molecular and Genetic Characterization of RCC” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Brian R. Lane, M.D., Associate Professor, Michigan State University discusses “Improving Healthcare Delivery in Kidney Cancer” at the 14th International Kidney Cancer Symposium (Kidney Cancer Association 25th Anniversary)

Dorothy Yang gives an overview of a study assessing the physical activity levels and barriers to exercise referral among patients with cancer, at the Bedford Hospital, Bedford, UK. The results of this study were presented at at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

James Larkin, MD, PhD gives an update on the clinical trial CheckMate 067, a phase 3 study of Nivolumab or Nivolumab plus Ipilimumab versus Ipilimumab alone in previously untreated advanced melanoma. This updated was presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.       update, update checkmate 067, phase 3 study, nivolumab, nivolumab plus ipilimumab, ipilimumab alone, in previously untreated advanced melanoma, advanced melanoma, ncri 2015, ncri, national cancer research institute, cancer conference

Robert Thomas, MbChb, MRCP, MD, FRCR, gives an overview of the session “Physical activity the panacea?” at the 2015 National Cancer Research Institute (NCRI) Cancer Conference.

Prof. Rob Coleman gives an overview of the session “This house believes we should stop focussing on the causes of breast cancer and get on with strategies to prevent the disease”, presented at the 2015 NCRI Cancer Conference. With Douglas Easton and Tim Key supporting the causes side, and Annie Anderson and Gareth Evans supporting the prevention side. The session was hosted by Prof. Rob Coleman.

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, discusses topics covered by scientists from the Francis Crick Institute at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. These include Tim Hunt, Richard Treisman, Nicholas Luscombe, Erik Sahai and Adrian Hayday. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the featured sessions of the 2015 National Cancer Research Institute (NCRI) Cancer Conference. These include sessions by Alberto Bardelli, Thierry Voet, Erik Sahai, Adrian Hayday, James Larkin, Sergio Quezada, Robert Peston and Fabrice André. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, gives an overview of the 2015 National Cancer Research Institute (NCRI) Cancer Conference, which will focus on integrating basic, translational and clinical cancer research, and cover topics such as cancer evolution, single cell genomics, cancer immunology, cancer cell cycle and health economics in cancer. Key speakers and hosts include Thierry Voet, Alberto Bardelli, Adrian Hayday, Sergio Quezada, Tim Hunt, Denis Slamon and Robert Peston. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Previously, risk reduction from treatment with endocrine therapy has been represented as a general percentage for all patients treated. Knowing that in reality each patient responds differently, Dr. Naughton stresses the importance of tailoring treatment decisions based on the individual patient situation. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses Trial Assigning IndividuaLized Options for Treatment (TAILORx), a prospective phase 3 clinical trial that was designed to evaluate the utility of the Oncotype DX® Breast Cancer Assay to risk stratify patients with oestrogen receptor-positive, HER2-negative, node-negative breast cancer. By identifying low-risk patients who are unlikely to benefit from adjuvant chemotherapy, the test may allow physicians to direct patients to individualised therapies that are associated with improved health outcomes. This content is supported by Genomic Health, Inc. European Medical Journal…

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses an open-label, biomarker-directed, multi-drug, multi-centre, multi-arm, randomised phase 1b clinical trial in patients with muscle-invasive urothelial carcinoma of the bladder who have progressed on prior treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Naughton discusses the bothersome side effects and serious safety risks associated with endocrine therapy. He emphasizes the need to weigh patient benefit versus the impact on quality of life due to these side effects and safety risks when considering patient treatment options. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, outlines potential therapeutic applications, including immune and adaptive approaches, of an improved understanding of cancer genes and mutational processes. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses Patient Reported Opinions about Clinical Tolerability (PROACT), a mobile platform designed to enable patients to directly contribute to the understanding of investigational agents in early clinical development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK, discusses a European Registration of Cancer Care (EURECCA) international comparison of treatment patterns for patients aged 70 years and older with non-metastatic breast cancer in four European countries. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Nancy Zhu – Case-Based Discussion for Managing MDS Patients. This live webinar took place on September 10, 2015.

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, explains that anti-tumour immunity has the potential to be exploited clinically against the evolutionary process that drives cancer development. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses the results from the European Thoracic Oncology Platform (ETOP) Lungscape Project, a study of the molecular epidemiology of resected stage I-III non-small cell lung cancer (NSCLC) tumours and association with clinicopathological features and outcomes in patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, reviews the emerging understanding of mutational drivers of tumour heterogeneity, including APOBEC-mediated mutagenesis, that could support the development of future therapeutic strategies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Martin Reck – ECC 2015 Immunotherapy Updates

@OncEd Presents Dr Luis Bruno – ECC 2015 GU Cancer Highlights (Portuguese Version)

@OncEd Presents Dr. Stephanie Snow – ECC 2015 Head and Neck Updates

@OncEd Presents Dr. Scott Berry – ICECREAM Trial

@OncED Presents Dr. Scott Berry – COMET Trial

@OncEd Presents Dr. Nadia Harbeck – PALOMA 3 Trial

@OncEd Presents Dr. Ralph Wong – Neuroendocrine Tumour Updates

@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter (Portuguese Version)

@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter

@OncEd Presents Dr. Silke Gillessen – SAKK 08/11 Study

@OncEd Presents Dr. Vladimir Milovanov – Predicting incomplete cytoreduction and aborted HIPEC in PC

@OncEd Presents Dr. Juan Pablo Marquez Manriquez – Multi-Antigen Vaccination for Colon Cancer Treatment and Prevention

@OncEd Presents Dr. Sunil Verma – ECC 2015 Breast Cancer Updates

@OncEd Presents Dr. Jeff Weber – Novel Combinations with Checkpoint Inhibitors

@OncEd Presents Dr. Stephen Doral Stefani – Access and Equity

@OncEd Presents Dr. Wolfgang Janni – DETECT Study

@OncEd Presents Dr. Jean Fayette – UNICANCER Trial

@OncEd Presents Dr Michael Untch – GEPARQUINTO Study

@OncEd Presents Dr. Fernando Rivera – PEAK Trial

At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queens University Belfast, Belfast, UK, Richard Sullivan, MD, PhD, of King’s College London, London, UK, and Francesco de Lorenzo, MD, of European Cancer Patient Coalition (ECPC), Brussels, Belgium, discuss the ECPC initiative, Europe of Disparities in Cancer, which was designed to evaluate the position of European cancer patients on the increasing inequalities in cancer care in Europe. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of recurrence and predictive factors to determine the optimal adjuvant therapy. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, discusses prognostic and predictive biomarkers that are enabling more individualised therapies to be applied in molecularly defined breast cancer subgroups. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

@OncEd Presents Dr. Christos Sotiriou – NEOALTTO Trial

@OncEd Presents Dr. Linda Lindstrom – ST03 Trial

@OncEd Presents Dr. Neal Shore – TAK-385 Trial

@OncEd Presents Visualization and relaxation as anxiety reducing techniques – Dr. Andreas Charalambous. From ECC 2015 in Vienna, Austria.

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a first-in-human study of the first-in-class fatty acid synthase inhibitor, TVB-2640, as monotherapy or in combination for the treatment of patients with solid malignancies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomised phase 3 clinical trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage 4 non-small cell lung cancer after disease progression on platinum-based therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr Naughton discusses challenges facing women who are evaluating extention of adjuvant endocrine treatment and how he finds Breast Cancer Index helpful.

At the European Cancer Congress (ECC) 2015, Peter Naredi, MD, PhD, of the University of Gothenburg, Gothenburg, Sweden, chairs a news briefing with Matteo Lambertini, MD, of IRCCS AOU San Martino-IST, Genova, Italy; Martine Frouws, MD, of Leiden University Medical Centre, Leiden, The Netherlands; and Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France. They discuss the results from a clinical trial evaluating post-diagnosis aspirin use; the Combi-v clinical trial; and an analysis of hormonal therapy for preventing ovarian failure and preserving fertility in breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation, representing 365 patient organisations in 40 European countries. The Europe of Disparities in Cancer initiative, a framework developed by ECPC, was designed to improve the survival and quality of life for cancer patients in Europe. Presented at the European Cancer Conference (ECC) 2015 by Francesco de Lorenzo, MD, of ECPC, Brussels, Belgium European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

There is a growing divide in cancer healthcare and survivorship between populations across Europe. European Cancer Patient Coalition (ECPC), the largest European cancer patients umbrella organisation, presented the paper, Europe of Disparities in Cancer, which discusses the position of European cancer patients on the increasing inequalities in cancer care in Europe, and provides a set of scientifically validated, patient-friendly, patient-oriented recommendations on the most important approaches to address these inequalities. Presented at the European Cancer Conference (ECC) 2015 by Richard Sullivan, MD, PhD, of King’s College London, London, UK European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses the first interim analysis of a phase 2, randomised, open-label, parallel group clinical trial of TAK-385, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of patients with advanced prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

European Cancer Patient Coalition (ECPC), the largest European cancer patients umbrella organisation, presented the paper, Europe of Disparities in Cancer, which discusses the position of European cancer patients on the increasing inequalities in cancer care in Europe. Europe of Disparities in Cancer is a scientifically validated, patient-friendly, patient-oriented set of recommendations on the most important approaches to address the inequalities in cancer care across Europe, including the need for better cancer health literacy, and access to cancer screening and early detection. Presented at the European Cancer Conference (ECC) 2015 by Mark Lawler, PhD, of Queens University Belfast, Belfast, UK European…

A meta-analysis was conducted to include 12 randomised trials and a total of 1,231 breast cancer patients receiving chemotherapy, with or without luteinising hormone-releasing hormone analogue (LHRHa). Initial results showed the rates of premature ovarian failure (POF) were reduced by 64% in patients who received LHRHa. However, the studies used different definitions of POF, and results ranged widely. The analysis was then restricted to trials that included specific data on whether a womans periods had re-started one year after chemotherapy. In the eight relevant trials, the rates of POF were reduced by 45% with LHRHa and there was close agreement…

Genomic interventions may improve disease-risk stratification and patient-tailored treatment. At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincents University Hospital, Dublin, Ireland, outlines the processes and challenges surrounding the health economic evaluation of genomic technologies in Europe. Clinical trials, such as the prospective validation of a 21-gene expression assay in breast cancer (Trial Assigning IndividuaLized Options for Treatment, TAILORx), are providing the data necessary to define the clinical utility of genomic profiling tests. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreview

At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincents University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx). TAILORx is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, node-negative breast cancer whose treatment was guided by the Oncotype DX® Breast Cancer Assay Recurrence Score® results. The results showed that adding genomic information provided by the Oncotype DX® Breast Cancer Assay may influence the selection of patients for adjuvant chemotherapy based on…

Results from a study in The Netherlands involving 13,715 patients showed that aspirin use after a cancer diagnosis significantly improved overall survival in patients diagnosed with a gastrointestinal cancer. In total, 30.5% of patients used aspirin pre-diagnosis, 8.3% were solely post-diagnosis users, and 61.1% had not taken aspirin at all. The commonest sites for tumours were colon (42.8% of patients), rectum (25.4%), and oesophagus (10.2%). Median follow-up time for all patients was 48.6 months, with 28% of patients surviving for at least five years. Patients using aspirin after their diagnosis had a chance of survival twice as high than that…

Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma showed that patients are living significantly longer on the combined therapy than patients treated with vemurafenib alone. The median overall survival time in patients with metastatic melanoma with V600 mutations in the BRAF gene who received the combination treatment was 25.6 months, whereas it was 18 months in patients receiving vemurafenib alone. Presented at the European Cancer Conference (ECC) 2015 by Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif,…

Genetic analysis of biopsies taken from the primary tumour, brain metastases and normal tissues of 104 adults with cancer found that, in every patient, the brain metastasis and primary tumour shared some of their genetics, but there were key differences. In 56% of patients, genetic alterations that potentially could be targeted with drugs were found in the brain metastasis but not in the primary tumour. In addition, it was found that if a patient had more than one brain metastasis, each was genetically similar and this data were used to map the evolution of a cancer through a patients body.…

At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses a phase 1b clinical trial that evaluated the safety and clinical activity of avelumab, a fully human anti-PD-L1 IgG1 antibody, for the treatment of patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx), which is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, axillary node-negative breast cancer whose treatment was guided by the 21-gene expression assay results, the Oncotype DX® Breast Cancer Assay Recurrence Score® results. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 12 metastatic midgut neuroendocrine tumours (NETs). The results to date showed 177Lu-DOTATATE provided a clinically meaningful and statistically significant increase in progression-free survival (PFS) in the patients treated with 177Lu-DOTATATE. Presented at the European Cancer Conference (ECC) 2015 by Philippe Ruszniewski, MD, of Beaujon Hospital, Clichy, France European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the US, showed that treatment with the mTOR inhibitor, everolimus, had a significant effect in non-functional neuroendocrine tumours (NETs). There was a statistically significant 52% reduction in the risk of progression or death in favour of everolimus, and also a clinically meaningful 2.8 fold (7.1 months) improvement in median progression-free survival compared with those who had taken placebo. Presented at the European Cancer Conference (ECC) 2015 by James Yao, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX…

The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is a pan-European organisation that represents professionals working in the field of childhood cancers. Although there has been considerable progress in the treatment of childhood cancers over the past few decades, and childhood cancer is rare, a SIOPE report suggests these are major problems that need to be overcome. The SIOPE Strategic Plan: A European Cancer Plan for Children and Adolescents is designed to improve the quality of life of survivors and cure rate of paediatric cancer patients within the next decade. Presented at the European Cancer Conference (ECC) 2015…

At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet, Brussels, Belgium, President of European CanCer Organisation (ECCO) and Congress Chair, chairs a news briefing with Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; Milena Sant, MD, of Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; and Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX. They discuss the results from the METEOR, CheckMate 025 and EUROCARE-5 clinical trials. European…

CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment, everolimus, in patients with clear cell renal cell carcinoma. CheckMate 025 is the first clinical trial to show an improvement in overall survival in these patients for any immune checkpoint inhibitor agent. The survival benefit was seen in patients regardless of the extent of the PD-1 ligand expression in their tumours. Presented at the European Cancer Conference (ECC) 2015 by Padmanee Sharma, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX European Medical Journal Website: http://emjreviews.com/…

Comparisons of cancer patients survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after diagnosis, there are large variations in survival between countries, which are particularly significant in blood cancers. New analysis of data from the EUROCARE-5 trial in patients diagnosed after 2000 in European countries revealed that survival is generally low in Eastern Europe and high in Northern and Central Europe, which confirms trends highlighted in previous EUROCARE studies. Presented at the European Cancer Conference (ECC) 2015 by Milena Sant, MD, of Istituto Nazionale per lo Studio e…

METEOR, a phase 3 clinical trial, compared cabozantinib, a novel receptor tyrosine kinase inhibitor, with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma. Analysis of the results in July 2015 showed that the estimated median progression-free survival time for patients in the trial, randomised to receive cabozantinib, was 7.4 months, whereas it was 3.8 months for those receiving everolimus. The objective response rate, assessed up to 17 months, was 21% for cabozantinib and 5% for everolimus. Presented at the European Cancer Conference (ECC) 2015 by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, Brigham and…

The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk categories in relation to the likelihood of breast cancer recurrence. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses adjuvant treatment decisions in early breast cancer patients with intermediate Oncotype DX RS results. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the results of the randomised, double-blind, phase 2 TERRAIN trial, which compared enzalutamide, a novel androgen receptor signalling inhibitor, with bicalutamide, a non-steroidal antiandrogen, for the treatment of men with metastatic castrate-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Hamilton appeared on Fox & Friends to discuss a new treatment option for HER2+ breast cancer, an aggressive form of breast cancer that can spread to the brain.

Dr. Bendell appeared on MSNBC to discuss former U.S. president Jimmy Carter’s melanoma diagnosis. Dr. Bendell discusses breakthroughs in treatment for melanoma including immunotherapy.

Dr. John Hainsworth of the Sarah Cannon Research Institute explains the different types of non-Hodgkin’s lymphoma.

Dr. Skip Burris on This Hour with Berman and Michael on CNN discussing cancer research in 2014.

Our physician experts appeared on Fox and Friends on 4/29 to discuss exciting new developments on the war on cancer. #fightingcancertogether

Dr. David Spigel on @FoxNews discussing exciting developments in #immunotherapy at the Annual ASCO Meeting

Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or unlikely to benefit from adjuvant chemotherapy. At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, outlines the approaches for effectively communicating personalised genomic disease-risk information to breast cancer patients. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the updated response and survival data of a phase 1a study of the anti-PDL1 antibody, MPDL3280A, for the treatment of patients with metastatic urothelial bladder cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses the controversy regarding the optimal approach to prognostic and predictive genomic testing for breast cancer. The Oncotype DX® Breast Cancer Assay, a 21-gene assay, may complement clinicopathological factors for defining subpopulations in breast cancer patients that would benefit from adjuvant chemotherapy. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the value of genomic tests for identifying breast cancer patients who are likely to benefit from neoadjuvant chemotherapy. Genomic testing may be beneficial for patients with intermediate-risk factors, as determined by classic clinicopathological tools, of tumour progression during therapy. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses the implications of routine Oncotype DX® testing for predicting the benefit of adjuvant chemotherapy in patients with early breast cancer. Dr Jaloudi outlines some of the challenges that need to be addressed to ensure continued access to well-validated genomic tests, such as the Oncotype DX® Breast Cancer Assay, in clinical practice. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses some of the difficulties with using Ki-67, a nuclear protein associated with cellular proliferation, as a predictive parameter for response to adjuvant chemotherapy in breast cancer patients. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses how genomic information from tests, such the Oncotype DX® Breast Cancer Assay, can be integrated with traditional clinicopathological information to support adjuvant clinical decision-making in breast cancer patients. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) While alkylators, IMiDs and proteasome inhibitors are current standard treatment for pts with MM, the presence of hypoxia in the diseased bone marrow (Colla, Leukemia 2010) presents a new therapeutic target for MM. TH-302 is a novel 2-nitroimidazole prodrug of the DNA alkylator bromo-isophosphoramide mustard that is selectively activated under hypoxia. Synergistic induction of apoptosis in MM cells by TH-302 and bortezomib was shown in MM models in vivo…

Saad Z. Usmani, MD Levine Cancer Institute – Morehead Charlotte, North Carolina, USA SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM) The introduction of immunomodulatory agents and proteasome inhibitors, and advances in high dose therapy administration have made an impact on progression free survival (PFS) and overall survival (OS) for multiple myeloma (MM) patients in general, but patients with HRMM still have a poor long-term prognosis. Therefore, it is imperative to develop novel therapeutic regimens that will extend PFS and OS in this group. The SWOG 1211 is the first…

Henk Lokhorst, MD University Medical Center Utrecht Utrecht, the Netherlands Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM) Pts with RR MM received DARA for 9 wks in doses of 0.005-24mg/kg in the GEN501 dose-escalation part (Lokhorst: EHA 2013 abstract S576). The purpose of the GEN501 expansion part, which has completed enrollment, was to evaluate safety and efficacy of 2 doses of DARA for up to 24 mths using alternate dose schedules Visit our website at: http://www.myeloma.org

Gunjan L. Shah, MD Tufts Medical Center Oncology Boston Massachusetts, USA Survival benefit and cost of autologous hematopoietic stem cell transplantation (Auto HSCT) in elderly patients with multiple myeloma (MM) using the SEER-Medicare database Medicare coverage for Auto HSCT for MM began in 10/2000. By 2009, MM was the leading indication for this treatment (CIBMTR, 2011). The survival benefit and cost implications of the rise in Auto HSCT are not well described in this population. Using SEER-Medicare data, we explored these implications for MM patients (pts) age 66+ by comparing them with pts not undergoing Auto HSCT. Visit our website…

David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN + DEX) Challenging relapsed disease with drugs of the same class remains an area of investigation. Subanalyses of MM-002 and MM-003 in advanced RRMM demonstrated comparable efficacy for POM + LoDEX in patients (pts) refractory to LEN as last prior treatment (Tx) vs. all pts (Richardson, 2014; San Miguel, 2013). To confirm this, MM-014, a multicenter, single-arm, open-label phase 2…

David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA A phase 1 (Ph1) trial of MK-3475 combined with lenalidomide (Len) and low-dose dexamethasone (Dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) RRMM patients refractory to proteasome inhibitors and immunomodulatory drugs (IMiD) have a very poor outcome. PD-L1 expressed on most MM plasma cells is a potential mechanism of immune evasion. MK-3475 is a potent, highly selective, humanized IgG4/kappa isotype, anti-PD-1 monoclonal antibody designed to block PD-1 interaction with PD-L1 and PD-L2, enhancing lymphocytic activity, tumor regression and immune rejection. Visit our website at: http://www.myeloma.org

David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM) Carfilzomib in combination with an immunomodulatory agent has proven efficacy in NDMM and RRMM. There is also synergistic activity of the combination of a proteasome inhibitor and a histone-deacetylase inhibitor Methods: To determine the toxicity and activity of the quadruplet using carfilzomib with lenalidomide, vorinostat and dexamethasone. The primary objectives were to determine the maximum tolerated dose (MTD) and the safety/tolerability of QUAD. Secondary objectives included ORR, DOR, TTP and TTNT.…

David Siegel, MD John Theurer Cancer Center Hackesack, New Jersey, USA Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies eIF5A has been implicated in the regulation of cell proliferation, apoptosis, and inflammation. It is the only known protein to be modified by hypusination, and is highly conserved across species and is active in plants and animals. Hypusinated eIF5A, the predominant form in normal and cancer cells, is involved in cell survival and…

Torben Plesner, MD Department of Hematology, Vejle Hospital Vejle, Denmark Daratumumab (DARA) (HuMax-CD38), a human IgG1? monoclonal antibody effectively mediates destruction of CD38-expressing malignant plasma cells. In the first-in-human dose-escalation study, 42% of heavily pretreated patients with relapsed or relapsed, refractory (RR) multiple myeloma (MM) treated with DARA alone (?4mg/kg) achieved partial response (PR) and 25% had minimal response (MR) (modified IMWG guidelines). In preclinical studies, DARA + lenalidomide (LEN) enhanced killing of MM cells in vitro.We evaluated safety, pharmacokinetics (PK) and efficacy of DARA + LEN + dexamethasone (DEX) in patients with relapsed or RR MM. Visit our website…

Matthias Weiss, MD Marshfield Clinic Marshfield, Wisconsin, USA ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCI–Trial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models. Accrual to NCI CTs is often slower than planned and at times mandating premature closure resulting in loss of valuable resources and delay of scientific progress. The NCI MYSC AWG identified 10 barriers to accrual (BtA) to MM CTs (reimbursement, competing treatment options, treatment at NCI designated sites only, etc.). The NCI-TCES was created to objectively assess CT complexity (study…

Jeremy Larsen, MD Mayo Clinic Rochester, Minnesota, USA Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma Translocation (4;14) and deletion 17p in smoldering multiple myeloma (SMM) have been identified as high risk cytogenetic abnormalities (CAs). Risk stratification incorporating CAs and biomarkers are needed to identify high risk SMM patients. The aim of this study was to determine the predictive value of the free light chain (FLC) assay in combination with high-risk CAs. Visit our website at: http://www.myeloma.org

Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma Panobinostat (PAN) is a potent pan-deacetylase inhibitor that demonstrates synergistic antimyeloma activity when combined with bortezomib (BTZ) + dexamethasone (Dex). Early studies demonstrated durable responses in patients (pts) with relapsed (Rel) and relapsed/refractory (RR) multiple myeloma (MM) treated with PAN + BTZ + Dex. This initiated the PANORAMA 1 study, presented herein. Visit our website at: http://www.myeloma.org

Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma. Combination treatment (Tx) with IMiDs immunomodulatory agents and PIs demonstrated substantial efficacy in myeloma patients (pts) (Richardson, Blood, 2010). MM-005 was designed to identify the optimal PVD dose for a phase 3 trial (MM-007) comparing PVD vs. BORT + LoDEX in RRMM pts. A secondary objective examined subcutaneous (SC) BORT as part of PVD Tx. Visit our website at: http://www.myeloma.org

Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) While alkylators, IMiDs and proteasome inhibitors are current standard treatment for pts with MM, the presence of hypoxia in the diseased bone marrow (Colla, Leukemia 2010) presents a new therapeutic target for MM. TH-302 is a novel 2-nitroimidazole prodrug of the DNA alkylator bromo-isophosphoramide mustard that is selectively activated under hypoxia. Synergistic induction of apoptosis in MM cells by TH-302 and bortezomib was shown in MM models in vivo…

Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA DETERMINATION trial: A phase III multi-center study examining the timing of stem cell transplant for MM The DETERMINATION study will have 1300 patients (700 in France and over 600 in the US) to determine when transplant is best used in newly diagnosed myeloma patients now that newer therapies are available. The study will also look at how the Revlimid/Velcade/Dex combo works as initial treatment and how lenalidomide affects progression as maintenance therapy. Visit our website at: http://www.myeloma.org

Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover Visit our website at: http://www.myeloma.org

Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover Visit our website at: http://www.myeloma.org

Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Treatment with immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) has dramatically increased response rates and survival for myeloma patients over the last decade. Triplet drug combinations are more effective than doublets or single agents. The more recently developed IMiD lenalidomide, with a different spectrum of effects to thalidomide, is an excellent option for induction therapy due to its oral administration and lack of significant peripheral neuropathy (PN) when compared with bortezomib and thalidomide. Visit our website at: http://www.myeloma.org

Angela Dispenzieri, MD Mayo Clinic Rochester, Minnesota, USA Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy (n.b., using modified measles vaccine) Visit our website at: http://www.myeloma.org

Xin Shelley Wang, MD MD Anderson Cancer Center Houston, Texas, USA Prevalence of high symptom burden and its impact on functioning and quality of life in patients with multiple myeloma 3-9 months following autologous transplant Although multiple myeloma (MM) patients are expected to have lower disease burden post autologous hematopoietic stem cell transplantation (AuSCT), symptom burden and its impact on patient’s quality of life (QoL) have not been prospectively studied in this time period, when maintenance therapy may be implemented. Visit our website at: http://www.myeloma.org

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United Arab Emirates, discusses the value of genomic profiling for individualising and improving adjuvant therapy for breast cancer patients. More recently, multigene assays, such as the Oncotype DX® Breast Cancer Assay, are being considered in addition to classic clinicopathological tools to guide treatment decisions for breast cancer patients. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Saad Z. Usmani, MD Levine Cancer Institute – Morehead Charlotte, North Carolina, USA Continuous lenalidomide (LEN) therapy versus observation following nonimmunomodulatory compound-based induction therapy in newly diagnosed multiple myeloma (NDMM): MM-027 trial Several recent trials have shown improvements in progression-free survival (PFS) with continuous LEN treatment (Tx) in NDMM patients (pts). PFS was 45%-59% higher using LEN therapy vs. control arm and rates of overall survival (OS) were consistently improved (Attal, NEJM 2012; Facon, ASH 2013, McCarthy, NEJM 2012; Palumbo, NEJM 2012, Palumbo ASCO 2013). Therefore an effective strategy of continuous Tx is of great importance to outcomes. Visit our…

Thomas G. Martin, MD University of California SF San Francisco, California, USA A phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma SAR650984 (SAR) is a humanized IgG1 monoclonal antibody that binds selectively to a unique epitope on human CD38 receptor. SAR kills tumor cells via antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, direct apoptosis induction without secondary crosslinking and allosteric inhibition on CD38 enzymatic activity. Visit our website at: http://www.myeloma.org

James R. Berenson, MD Institute for Myeloma & Bone Cancer Research West Hollywood, California, USA Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US for the treatment of relapsed and refractory multiple myeloma (MM). This multicenter, single-arm phase 1/2 study (NCT01677858) is evaluating the safety and efficacy of once-weekly CFZ with dexamethasone (DEX). Visit our website at: http://www.myeloma.org

Thomas G. Martin, MD University of California SF San Francisco, California, USA A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma SAR650984 (SAR) is a naked humanized IgG1 monoclonal antibody that binds to the CD38 receptor. SAR kills tumor cells via ADCC, CDC, direct apoptosis without secondary crosslinking and allosteric inhibition on CD38 enzymatic activity. Data on relapsed /refractory multiple myeloma (RRMM) patients (pts) in the dose escalation phase of the study are reported. (NCT01084252). Visit our website at: http://www.myeloma.org

Antonio Palumbo, MD University of Torino Torino Italy Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints Continuous therapy significantly prolongs remission duration, resistant relapse may reduce the duration of subsequent remission which can negatively impact on OS. PFS1 defines the time from start of therapy to the occurrence of 1st relapse. PFS2 is defined as per EMA as the time from start of therapy to the occurrence of 2nd relapse, incorporating the duration of both 1st and 2nd remission. We evaluated PFS1, PFS2 and OS in newly diagnosed multiple myeloma…

Keith K. Stewart, MB ChB Mayo Clinic Scottsdale, Arizona, USA E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma (MM) Melphalan, prednisone and thalidomide (MPT) is an accepted regimen in newly diagnosed MM. Early studies suggested that lenalidomide (R) might be substituted for thalidomide (T) with equal efficacy and less toxicity. We present E1A06, a randomized, multicenter phase 3 trial comparing MPT vs. MPR in pts with untreated, symptomatic, transplant ineligible MM. Visit our website at: http://www.myeloma.org

Mark A. Fiala, BS, CCRN Washington University School of Medicine Division of Oncology, Department of Medicine Saint Louis, MO, USA The Impact of Race and Socio-Economic Status on Survival in Multiple Myeloma Advances in multiple myeloma (MM) therapies have improved overall survival (OS), however, not all population subgroups have benefited equally from these advances. Population-based studies suggest that black patients (pts) with MM have a much higher mortality rate than white pts, however, in several studies, after controlling for treatment, OS was similar or superior for black pts. This discrepancy suggests that the poorer outcomes observed in black pts are…

Dr. Paul Richardson Dana-Farber Cancer Institute Boston, Massachusetts, USA Visit our website at: http://www.myeloma.org

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains that the use of genomic tests for breast cancer patients in clinical practice is affected by numerous factors, including the ability of the test to predict response to treatment and the ability of the test to provide meaningful prognostic information in addition to the information provided by classic clinicopathologic tools. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)

Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)